MedPath

SUBOXONE

SUBOXONE

Approved
DIN Number

02502321

Drug Class

Human

Market Date

Jun 17, 2021

Company
HC

INDIVIOR UK LIMITED

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02502321
AIG Number0252216005
Classification & Schedule
C
Drug Class
Human
S
Schedule
Narcotic (CDSA I)
A
ATC Code
N07BC51 BUPRENORPHINE, COMBINATIONS
Product Specifications
Dosage FormFilm, Soluble
Route of AdministrationSublingual ,  Buccal
AHFS Classification28:08.12
Health Canada Classification

ACTIVE INGREDIENTS (2)

BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE)Active
Strength: 4 MG
Monograph: BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE)
NALOXONE (NALOXONE HYDROCHLORIDE)Active
Strength: 1 MG
Monograph: NALOXONE (NALOXONE HYDROCHLORIDE)

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.